Alejandra Bernardini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alejandra Bernardini has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
- Jesus Maria Paramio
Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), 28041 Madrid, Spain
17 shared publications Carolina Rubio
13 shared publicationsCristina Segovia
13 shared publications- Ester Munera-Maravilla
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) Monforte de Lemos 3, 5, 28029 Madrid, Spain
13 shared publications Mónica Martínez-Fernández
13 shared publicationsCarmen Segrelles
12 shared publications
Latest Publications
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status
Includes Supplementary Figures 1-13; Supplementary Tables 1, 2, 3, 7 and 8; and Supplementary References
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status
Includes Supplementary Figures 1-13; Supplementary Tables 1, 2, 3, 7 and 8; and Supplementary References
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status
Supplementary Table 6: Spreadsheet of transcriptomic data
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status
Supplementary Table 6: Spreadsheet of transcriptomic data
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status
Supplementary Table 4: Spreadsheet of transcriptomic data
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status
Supplementary Table 4: Spreadsheet of transcriptomic data
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status
Purpose:Bladder cancer is a clinical and social problem due to its high incidence and recurrence rates. It frequently appears in elderly patients showing other medical comorbidities that hamper the use of standard chemotherapy. We evaluated the activity of CDK4/6 inhibitor as a new therapy for patients unfit for cisplatin (CDDP).Experimental Design:Bladder cancer cell lines were tested for in vitro sensitivity to CDK4/6 inhibition. A novel metastatic bladder cancer mouse model was developed and used to test its in vivo activity.Results:Cell lines tested were sensitive to CDK4/6 inhibition, independent on RB1 gene status. Transcriptome analyses and knockdown experiments revealed a major role for FOXM1 in this response. CDK4/6 inhibition resulted in reduced FOXM1 phosphorylation in vitro and in vivo and showed synergy with CDDP, allowing a significant tumor regression. FOXM1 exerted important oncogenic roles in bladder cancer.Conclusions:CDK4/6 inhibitors, alone or in combination, are a novel therapeutic strategy for patients with advanced bladder cancer previously classified as unfit for current treatment options.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status
Purpose:Bladder cancer is a clinical and social problem due to its high incidence and recurrence rates. It frequently appears in elderly patients showing other medical comorbidities that hamper the use of standard chemotherapy. We evaluated the activity of CDK4/6 inhibitor as a new therapy for patients unfit for cisplatin (CDDP).Experimental Design:Bladder cancer cell lines were tested for in vitro sensitivity to CDK4/6 inhibition. A novel metastatic bladder cancer mouse model was developed and used to test its in vivo activity.Results:Cell lines tested were sensitive to CDK4/6 inhibition, independent on RB1 gene status. Transcriptome analyses and knockdown experiments revealed a major role for FOXM1 in this response. CDK4/6 inhibition resulted in reduced FOXM1 phosphorylation in vitro and in vivo and showed synergy with CDDP, allowing a significant tumor regression. FOXM1 exerted important oncogenic roles in bladder cancer.Conclusions:CDK4/6 inhibitors, alone or in combination, are a novel therapeutic strategy for patients with advanced bladder cancer previously classified as unfit for current treatment options.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status
Purpose:Bladder cancer is a clinical and social problem due to its high incidence and recurrence rates. It frequently appears in elderly patients showing other medical comorbidities that hamper the use of standard chemotherapy. We evaluated the activity of CDK4/6 inhibitor as a new therapy for patients unfit for cisplatin (CDDP).Experimental Design:Bladder cancer cell lines were tested for in vitro sensitivity to CDK4/6 inhibition. A novel metastatic bladder cancer mouse model was developed and used to test its in vivo activity.Results:Cell lines tested were sensitive to CDK4/6 inhibition, independent on RB1 gene status. Transcriptome analyses and knockdown experiments revealed a major role for FOXM1 in this response. CDK4/6 inhibition resulted in reduced FOXM1 phosphorylation in vitro and in vivo and showed synergy with CDDP, allowing a significant tumor regression. FOXM1 exerted important oncogenic roles in bladder cancer.Conclusions:CDK4/6 inhibitors, alone or in combination, are a novel therapeutic strategy for patients with advanced bladder cancer previously classified as unfit for current treatment options.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status
Purpose:Bladder cancer is a clinical and social problem due to its high incidence and recurrence rates. It frequently appears in elderly patients showing other medical comorbidities that hamper the use of standard chemotherapy. We evaluated the activity of CDK4/6 inhibitor as a new therapy for patients unfit for cisplatin (CDDP).Experimental Design:Bladder cancer cell lines were tested for in vitro sensitivity to CDK4/6 inhibition. A novel metastatic bladder cancer mouse model was developed and used to test its in vivo activity.Results:Cell lines tested were sensitive to CDK4/6 inhibition, independent on RB1 gene status. Transcriptome analyses and knockdown experiments revealed a major role for FOXM1 in this response. CDK4/6 inhibition resulted in reduced FOXM1 phosphorylation in vitro and in vivo and showed synergy with CDDP, allowing a significant tumor regression. FOXM1 exerted important oncogenic roles in bladder cancer.Conclusions:CDK4/6 inhibitors, alone or in combination, are a novel therapeutic strategy for patients with advanced bladder cancer previously classified as unfit for current treatment options.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status
Supplementary Table 5: Spreadsheet of transcriptomic data
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status
Supplementary Table 5: Spreadsheet of transcriptomic data
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status
Supplementary Table 5: Spreadsheet of transcriptomic data
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status
Supplementary Table 5: Spreadsheet of transcriptomic data
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status
Includes Supplementary Figures 1-13; Supplementary Tables 1, 2, 3, 7 and 8; and Supplementary References
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status
Includes Supplementary Figures 1-13; Supplementary Tables 1, 2, 3, 7 and 8; and Supplementary References
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status
Supplementary Table 4: Spreadsheet of transcriptomic data
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status
Supplementary Table 4: Spreadsheet of transcriptomic data
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status
Supplementary Table 6: Spreadsheet of transcriptomic data
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status
Supplementary Table 6: Spreadsheet of transcriptomic data